IMF Patient & Family Webinar - Back to Basics: From Testing to Tailored Therapy
Saturday, August 20, 2022
10 a.m. PST / 11 a.m. MST
12 p.m. CT/ 1 p.m. ET
IMF Patient and Family Webinar
IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie will moderate presentations with the following myeloma experts:
- Paul Richardson, MD (Dana-Farber Cancer Institute, Boston, MA)
- Saad Usmani, MD (Memorial Sloan Kettering Cancer Center, New York, NY)
- Mary Steinbach, DNP, APRN (Hunstman Cancer Institute, Salt Lake City, UT)
What to Expect
Dr. Brian G.M. Durie will kick off the webinar with Recommended Testing and Monitoring: 2022 Algorithms—a discussion which will cover required testing for diagnosis and monitoring, new testing approaches, as well as Mass Spectrometry and molecular analyses. 2022/2023 Myeloma care guidelines throughout the disease course will also be presented, with an open discussion of key options. The presentation will end with a Q&A session.
Next, Dr. Paul Richardson will discuss Frontline Options, where frontline therapy will be discussed in the context of the role of autologous stem cell transplant (ASCT) and the use of quadruplets (four-drug combinations) vs triplets (three-drug combinations). The results of the DETERMINATION Trial (Triplet VRd +/- upfront ASCT) will be the starting point for discussions and questions.
A panel discussion will follow this session before the short break.
In the next segment, IMF Nurse Leadership Board (NLB) Member Mary Steinbach will discuss Managing Myeloma Care, where questions about the overall approach to supportive care will be answered. It is particularly important to review and open discussions about special side effects and/or toxicities brought about by new and emerging therapies.
In the final presentation, Relapse Options: FDA Approved/Clinical Trials, Dr. Usmani will be discussing how to manage relapsing disease from the perspective of both currently approved and available therapies, as well as clinical trial options. He will particularly focus on the potential role of bispecific antibodies in new and emerging treatment paradigms—an area with many questions that need to be addressed. A Q&A session will follow at the end of the presentation.
The webinar will conclude with a summary panel discussion, a webinar survey, and closing remarks.
You won’t want to miss this lively webinar. At the end of the presentations, participants will have time to ask questions.
If you miss the webinar, a replay will be available afterwards, with participants' questions at the end.
Acquaint yourselves with the following resources on the IMF website to better understand the discussions.
*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:
- CANOVA Clinical Trial Fact Sheet
clinicaltrials.gov Identifier: NCT03539744
- Phase II Relapsed or Refractory Venetoclax Trial
clinicaltrials.gov Identifier: NCT02899052
- Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib
clinicaltrials.gov Identifier: NCT03314181
Watch Ask Dr. Durie Videos:
Download the IMF's Multiple Myeloma Informational Booklets:
Patient and Family Webinar Sponsors:
with support from:
Amgen, The Binding Site, Bristol Myers Squibb, Genentech/Roche, GSK, Janssen, Karyopharm, Sanofi, and Takeda Oncology
Please check out these multiple myeloma resources from our sponsors:
|Even The Odds|
|Virtual Patient Booth|